<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02523768</url>
  </required_header>
  <id_info>
    <org_study_id>0908143</org_study_id>
    <secondary_id>2009-018189-36</secondary_id>
    <secondary_id>A100405-32</secondary_id>
    <nct_id>NCT02523768</nct_id>
  </id_info>
  <brief_title>Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment</brief_title>
  <acronym>PIRAT</acronym>
  <official_title>Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      IgA nephropathy (IgAN) is a histologically defined glomerulonephritis (renal biopsy) by the
      presence of deposits immunoglobulin A (IgA) in the renal mesangium (at least 1+) by
      immunofluorescence. The clinic allows excluding secondary forms (10-15%). Recurrence of this
      condition on the renal graft is time-dependent and confirmed in 25 to 50% of 10 years
      post-transplant.

      The primary immunosuppressive induction regimens currently used in kidney transplantation are
      the anti-lymphocyte globulin (GAL) whose main target is human T lymphocytes (ATG, polyclonal)
      and monoclonal anti-CD25 antibodies (α chain of the interleukin receptor 2 in the surface of
      T lymphocytes). Due to their potent and prolonged immunosuppressive properties, the ATG may
      prevent or delay the recurrence on renal transplant.

      The aim of this study was to evaluate the influence of induction therapy (ATG versus
      Basiliximab) in the cumulative incidence at 5 years of (IgAN) recurrence after a first kidney
      transplant.

      This is a prospective, multicenter, randomized, open trial with a follow-up period of 5 years
      old.

      Patients in the ATG arm will receive 5 antilymphocyte globulin infusions Fresenius® (rabbit
      immunoglobulin antilymphocyte human T-Fresenius® said ATG) from Day 0 to Day + 4
      post-transplant (day 0 one dose of 4mg / kg, day 1 one dose of 4mg/kg, day2 one dose of
      4mgkg, day 3 one dose of 3 m/kg and day 4 and one final dose of 3 mg/kg) and the patients in
      the anti-CD25 arm will receive 2 doses of 20 mg of basiliximab (Simulect®) pn day 0 and day 4
      after the graft. The maintenance immunosuppressive therapy is left to the discretion of the
      center.

      The primary endpoint will be the clinical and histological recurrence of IgAN defined by the
      presence of mesangial deposits of IgA (at least 1) by immunofluorescence on a biopsy of the
      graft triggered by the onset of proteinuria 1g/j and/or microalbuminuria greater than 300 mg
      / day.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>onset of proteinuria 1g / j and / or microalbuminuria greater than 300 mg / day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>histological recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>histological recurrence defined by the presence of mesangial deposits of IgA (at least 1+) by immunofluorescence on a biopsy of the graft</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>Glomerulonephritis</condition>
  <condition>IgAN</condition>
  <arm_group>
    <arm_group_label>ATG-F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The ATG-Fresenius® is administered by slow infusion over four hours after antihistamine (2 bulbs Polaramine® IV) and intravenous methylprednisolone (minimum 30mg); it is started on day 0 prior to surgery at doses of 4 mg / kg, and then continued to day 1, day 2 to 4mg / kg, then day 3, day 4 at the dose of 3 mg / kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simulect</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The anti CD25 (basiliximab, Simulect®) is administered intravenously before surgery of renal transplantation (Day 0 and Day + 4 (1 ampoule of 20 mg x 2 times).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG-F</intervention_name>
    <arm_group_label>ATG-F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simulect</intervention_name>
    <arm_group_label>Simulect</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Free, informed, express and written.

          -  Diagnosis of native kidney primary IgA glomerulonephritis biopsy-proven

          -  First kidney transplantation (one kidney)

        Exclusion Criteria:

          -  Panel Reactive Antibody (PRA PRA global or class I or class II PRA) over 50% on a
             serum before transplantation

          -  Multi-organ graft

          -  Transplants using donor limits or sub-optimal: donor age ≥ 70 years, donors in the
             study BIGRAS or taken heart beating donors (tested on computer infusion) or other
             restriction factors

          -  IgA glomerulonephritis secondary to HSP (Henoch-Schonlein purpura) or Systemic Lupus
             Erythematosus (SLE) or alcoholic cirrhosis

          -  History of cancer older than 5 years or with advanced cancer, but except for
             non-recurrent skin cancers

          -  Infectious diseases scalable: tuberculosis, HIV, Hepatitis B virus or Hepatitis C
             virus infection with viral replication and / or chronic hepatitis

          -  Allergy to rabbit proteins

          -  Severe thrombocytopenia (&lt;50,000 platelets/ul)

          -  Bacterial infection, viral and fungal uncontrolled therapeutically

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francois BERTHOUX, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de SAINT-ETIENNE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de BESANCON</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de BORDEAUX</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Kremlin Bicetre</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard HERRIOT</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de MONTPELLIER</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de NANCY</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de NANTES</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de NICE</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital LYON Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de SAINT-ETIENNE</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de STRASBOURG</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de TOULOUSE</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de TOURS</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2015</study_first_submitted>
  <study_first_submitted_qc>August 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2015</study_first_posted>
  <last_update_submitted>September 25, 2017</last_update_submitted>
  <last_update_submitted_qc>September 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
    <mesh_term>Glomerulonephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunosuppressive Agents</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

